875 related articles for article (PubMed ID: 11776302)
1. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
2. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
Gibson JL; Ekevall K; Walker I; Greer IA
Br J Obstet Gynaecol; 1998 Jul; 105(7):795-7. PubMed ID: 9692422
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
Ismail SK; Norris L; Muttukrishna S; Higgins JR
Thromb Res; 2012 Nov; 130(5):799-803. PubMed ID: 22365560
[TBL] [Abstract][Full Text] [Related]
4. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
5. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
Hiscock RJ; Casey E; Simmons SW; Walker SP; Newell PA
Int J Obstet Anesth; 2013 Nov; 22(4):280-8. PubMed ID: 23958275
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
7. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
8. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
9. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
10. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
Morris TA; Jacobson A; Marsh JJ; Lane JR
Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
[TBL] [Abstract][Full Text] [Related]
12. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Sassi M; Chakroun T; Mbemba E; Van Dreden P; Elalamy I; Larsen AK; Gerotziafas GT
Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
[TBL] [Abstract][Full Text] [Related]
13. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.
Bombeli T; Raddatz Mueller P; Fehr J
Haemostasis; 2001; 31(2):90-8. PubMed ID: 11684864
[TBL] [Abstract][Full Text] [Related]
16. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
17. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
20. Prevention of venous thromboembolism in pregnancy.
Greer IA
Eur J Med Res; 2004 Mar; 9(3):135-45. PubMed ID: 15096324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]